Last reviewed · How we verify

GSK1024805A — Competitive Intelligence Brief

GSK1024805A (GSK1024805A) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: LPA1 receptor antagonist. Area: Fibrosis / Immunology.

phase 3 LPA1 receptor antagonist LPA1 (lysophosphatidic acid receptor 1) Fibrosis / Immunology Biologic Live · refreshed every 30 min

Target snapshot

GSK1024805A (GSK1024805A) — GlaxoSmithKline. GSK1024805A is a lysophosphatidic acid receptor 1 (LPA1) antagonist that blocks LPA-mediated signaling to reduce fibrotic and inflammatory responses.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
GSK1024805A TARGET GSK1024805A GlaxoSmithKline phase 3 LPA1 receptor antagonist LPA1 (lysophosphatidic acid receptor 1)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (LPA1 receptor antagonist class)

  1. GlaxoSmithKline · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). GSK1024805A — Competitive Intelligence Brief. https://druglandscape.com/ci/gsk1024805a. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators: